Furthermore, our subsequent decay functions and CD4:CD8 ratio loss rates also suggested that, among Class 2 participants, there was a significant CD4:CD8 ratio decline among those who developed CKD starting at 5.5–6.5 years of follow-up (a CD4:CD8 ratio < 0.10); or a decline of 45% from baseline values. Here, CD8A is linked to chronic kidney disease.